Skip to main content
European Commission logo print header

The Fungal cell wall as a target for antifungal therapies

Cel

Fungal pathogens represent the major eukaryotic agents of serious infection in European countries. Infections due to Candida albicans and Aspergillus fumigatus are the most common and clinically important pathogens and are therefore the focus of this project. The repertoire of available antifungal chemotherapeutic agents is inadequate to treat life-threatening infections that are characterized by morbidities that exceed those due to most important bacterial and viral diseases. Therefore there is an urgent need to generate new, efficacious, non-toxic compounds with broad-spectrum antifungal activity. The fungal wall is the skeleton and armour of the fungus but potentially also its Achilles heel since the major components are absent from mammals and can be specifically targeted with compounds that do not affect human metabolism. We have focused our programme on the core cell wall structure that is common to all fungal pathogens and is essential for their growth and viability. This core consists of the component polysaccharides 1-3 glucan and chitin, which are cross-linked to each other. The enzymes and reactions associated with the synthesis and the remodeling of these major cell wall polysaccharides as well as the sensing mechanisms important in cell wall integrity and remolding during morphogenetic processes will be investigated. The challenge for this STREP is investigate mechanisms of fungal cell wall synthesis in order to identify new antifungal targets to control human fungal infections in Europe.

Zaproszenie do składania wniosków

FP6-2003-LIFESCIHEALTH-I
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

INSTITUT PASTEUR
Wkład UE
Brak danych
Adres
25-28, rue du Docteur Roux
PARIS
Francja

Zobacz na mapie

Linki
Koszt całkowity
Brak danych

Uczestnicy (9)